Arcturus Therapeutics Holdings, Inc. (ARCT)
13.79
+0.92
(+7.15%)
USD |
NASDAQ |
Oct 09, 14:25
Arcturus Therapeutics Holdings Enterprise Value : 197.25M for Oct. 8, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 08, 2026 | 197.25M |
| October 07, 2026 | 194.27M |
| October 06, 2026 | 200.95M |
| October 05, 2026 | 248.13M |
| October 02, 2026 | 201.80M |
| October 01, 2026 | 206.92M |
| September 30, 2026 | 220.56M |
| September 29, 2026 | 220.85M |
| September 28, 2026 | 242.45M |
| September 25, 2026 | 225.11M |
| September 24, 2026 | 232.78M |
| September 23, 2026 | 209.48M |
| September 22, 2026 | 240.17M |
| September 21, 2026 | 248.98M |
| September 18, 2026 | 287.07M |
| September 17, 2026 | 312.65M |
| September 16, 2026 | 274.85M |
| September 15, 2026 | 281.67M |
| September 14, 2026 | 266.04M |
| September 11, 2026 | 250.12M |
| September 10, 2026 | 228.80M |
| September 09, 2026 | 250.40M |
| September 08, 2026 | 275.70M |
| September 04, 2026 | 281.10M |
| September 03, 2026 | 273.71M |
| Date | Value |
|---|---|
| September 02, 2026 | 307.25M |
| September 01, 2026 | 292.61M |
| August 31, 2026 | 250.97M |
| August 28, 2026 | 263.20M |
| August 27, 2026 | 291.05M |
| August 26, 2026 | 281.39M |
| August 25, 2026 | 270.30M |
| August 24, 2026 | 239.04M |
| August 21, 2026 | 213.74M |
| August 20, 2026 | 143.82M |
| August 19, 2026 | 123.64M |
| August 18, 2026 | 64.80M |
| August 17, 2026 | 62.81M |
| August 14, 2026 | 65.37M |
| August 13, 2026 | 54.85M |
| August 12, 2026 | 47.46M |
| August 11, 2026 | 45.19M |
| August 10, 2026 | 31.83M |
| August 07, 2026 | 42.06M |
| August 06, 2026 | 4.262M |
| August 05, 2026 | 9.378M |
| August 04, 2026 | 8.241M |
| August 03, 2026 | 1.988M |
| July 31, 2026 | -4.834M |
| July 30, 2026 | -0.2858M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.488B |
| Exelixis, Inc. | 14.02B |
| Ionis Pharmaceuticals, Inc. | 7.307B |
| United Therapeutics Corp. | 20.08B |
| PTC Therapeutics, Inc. | 3.680B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -23.78M |
| Revenue (Quarterly) | 0.88M |
| Total Expenses (Quarterly) | 24.66M |
| EPS Diluted (Quarterly) | -0.8368 |
| Gross Profit Margin (Quarterly) | 31.82% |
| Profit Margin (Quarterly) | -2.70K% |
| Earnings Yield | -24.04% |
| Normalized Earnings Yield | -22.67 |